Arm

Falls, fractures and self-harm: 4 charts on how kids’ injury risk changes over time and differs for boys and girls

Retrieved on: 
Thursday, April 18, 2024

At least a quarter of all emergency department presentations during childhood are injury-related.

Key Points: 
  • At least a quarter of all emergency department presentations during childhood are injury-related.
  • Injuries can be unintentional (falls, road crashes, drowning, burns) or intentional (self harm, violence, assault).
  • The type, place and cause of injury differs by age, developmental stage and sex.


children aged 1–4 years are the age group most likely to present to an emergency department with injuries
adolescents aged 16–18 years are the age group most likely to be admitted to hospital for injuries
boys are more likely to be hospitalised for injuries than girls. This continues into adulthood
girls are five times more likely to be hospitalised for intentional self-harm injuries than boys
falls are the leading cause of childhood injury, accounting for one in three child injury hospitalisations. Falls from playground equipment are the most common
fractures are the most common type of childhood injury, especially arm and wrist fractures in children aged 10–12 years.

  • For children under age one, drowning, burns, choking and suffocation had the highest injury hospital admission rates compared to adults.
  • In early childhood (ages 1-4 years), the highest causes of injury hospitalisation were drowning, burns, choking and suffocation and accidental poisoning.

What about sports?

  • Cycling causes the highest number of sporting injuries with almost 3,000 injury hospital presentations.
  • For the top 20 sports that are most likely to cause injury hospital admissions, fractures are the most common type of injury.
  • How to spot a serious injury now school and sport are back

Balancing risk and safety

  • To prevent injuries, we need to balance risk and safety.
  • Embracing risk is a fundamental part of play in all environments where children play and explore their world.
  • But with proper guidance and supervision from parents and caregivers, we can strike a balance between offering opportunities for risk-taking and ensuring children’s safety from serious harm.

What can governments do to prevent injuries?

  • This will provide clear guidance for all levels of government and others on prevention strategies and investment needed.
  • Better reporting on childhood and adolescent injury trends will better inform parents, caregivers, teachers and health professionals about the risks.
  • She is currently undertaking a project specific short term contract at the AIHW, in the Family and Domestic Violence Unit.
  • Dr Sharwood is recognised as a Professional Fellow in the Faculty of Engineering and IT, UTS, for her industry expertise in product related injuries.
  • Warwick Teague is Director of Trauma and Consultant Paediatric Surgeon at The Royal Children's Hospital Melbourne (RCH).

HDBank increases ‘green’ credit to help popularise Vietnamese rice globally

Retrieved on: 
Wednesday, April 10, 2024

Prime Minister Phạm Minh Chính issued Directive No 10/CT-TTg on March 2, 2024, on promoting the production, trading and export of rice in a sustainable, transparent and effective manner.

Key Points: 
  • Prime Minister Phạm Minh Chính issued Directive No 10/CT-TTg on March 2, 2024, on promoting the production, trading and export of rice in a sustainable, transparent and effective manner.
  • It focuses on meeting credit needs for buying and exporting rice from the 2023-2024 winter-spring crop in the Mekong Delta.
  • Lộc Trời was also the first enterprise to put Vietnamese rice on the shelves of E.Leclerc, which has nearly 600 hypermarkets and more than 100 supermarkets across France.
  • In recent years Việt Nam's rice industry has had outstanding success, reaching world levels and establishing its position.

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

Retrieved on: 
Monday, April 8, 2024

“OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.

Key Points: 
  • “OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.
  • Until now, there has been only one marketed product to treat one of the 100 gene mutations associated with RP.
  • In the Phase 1/2 OCU400 clinical trial, a Multi-Luminance Mobility Testing (MLMT) scale was the primary functional endpoint.
  • With the initiation of the Phase 3 clinical trial, OCU400 remains on track for the 2026 BLA approval target.

Synaptics Astra™ AI-Native IoT Platform Launches with SL-Series Embedded Processors and Machina Foundation Series Development Kit

Retrieved on: 
Monday, April 8, 2024

SAN JOSE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA ) today launched the Synaptics Astra platform with the SL-Series of embedded AI-native Internet of Things (IoT) processors and the Astra MachinaTM Foundation Series development kit.

Key Points: 
  • SAN JOSE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA ) today launched the Synaptics Astra platform with the SL-Series of embedded AI-native Internet of Things (IoT) processors and the Astra MachinaTM Foundation Series development kit.
  • The family of embedded processors provides industry-leading compute capability at power-consumption levels that enable a wide range of consumer, enterprise, and industrial edge IoT applications.
  • The Astra Machina Foundation Series development kit supports the SL-Series.
  • The Astra Machina Foundation Series development kit will be available in Q2, 2024.

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Retrieved on: 
Saturday, April 6, 2024

BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension (reported together as “glaucoma”, below) The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Key Points: 
  • “Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study.
  • We designed the Phase 2 clinical trial to evaluate PAXTRAVA over several time points that we believe are clinically meaningful, through six months.
  • Most ocular AEs within 3 days were deemed related to the injection procedure by the investigators.
  • I am enthusiastic about PAXTRAVA because of the positive, durable IOP reductions, accompanied by a good overall safety profile,” said Mark Gallardo, MD.

Himax to Unveil Revolutionary Ultralow Power Contactless Palm Vein Authentication Technology, WiseEye Vein, at ISC West

Retrieved on: 
Wednesday, April 3, 2024

WiseEye Vein revolutionizes next-generation access control with its exceptionally low power consumption, making it possible for palm vein authentication to be applied in battery-powered endpoint devices.

Key Points: 
  • WiseEye Vein revolutionizes next-generation access control with its exceptionally low power consumption, making it possible for palm vein authentication to be applied in battery-powered endpoint devices.
  • WiseEye Vein is powered by Himax WiseEye AI solution featuring WiseEye2, Himax's second-generation AI processor, NIR CMOS image sensor, and proprietary AI inference model for palm vein authentication.
  • Meanwhile, WiseEye Vein offers exceptional accuracy compared to other biometric methods, due to the unique and intricate pattern of veins in the palm.
  • Himax invites all interested parties to stop by our exhibition at booth 4135 at Venetian Expo, Las Vegas during ISC West 2024.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Retrieved on: 
Tuesday, April 2, 2024

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.

Key Points: 
  • We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.
  • The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily.
  • All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive.
  • The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System

Retrieved on: 
Tuesday, April 2, 2024

EINDHOVEN, the Netherlands, April 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to improve or restore movement, function, and independence in people with spinal cord injury (SCI), today announces it has submitted its De Novo application to the US Food and Drug Administration (FDA) to allow marketing of its breakthrough ARC-EX System to restore function of the upper extremities after SCI.

Key Points: 
  • The submission marks an historic milestone for the Company in its mission to restore mobility and function for people with SCI.
  • Once cleared by the FDA, ARC-EX will be the first-ever spinal cord stimulation therapy to restore hand and arm function after SCI and the first commercial product for ONWARD Medical.
  • “We are delighted to be one step closer to bringing our breakthrough ARC-EX System to people living with SCI after submitting this De Novo application for regulatory clearance in the United States,” said ONWARD Medical CEO Dave Marver.
  • The ARC-EX System was previously awarded FDA Breakthrough Device Designation (BDD) for upper limb function, which provided prioritized FDA review, the opportunity to interact with FDA experts, and the potential for additional reimbursement.

Canon Adds Powerful Scanning Capabilities to its imagePROGRAF Printer Portfolio with Two WideTEK® Scanners from Image Access

Retrieved on: 
Thursday, March 28, 2024

The Image Access WideTEK® 36CL CIS scanner is ideal for scanning text documents and CAD drawings up to 36” wide, and the Image Access WideTEK® 48 CCD scanner designed for scanning artwork, photographs, and related images up to 48” wide.

Key Points: 
  • The Image Access WideTEK® 36CL CIS scanner is ideal for scanning text documents and CAD drawings up to 36” wide, and the Image Access WideTEK® 48 CCD scanner designed for scanning artwork, photographs, and related images up to 48” wide.
  • The WideTEK® 36CL produces extraordinarily sharp images, with high color accuracy, even superior to competing CCD scanners on the market today.
  • The WideTEK® 48 CCD scanner can digitize graphics documents up to 48 inches wide at astonishingly fast speeds.
  • These scanners are an addition to Canon’s current lineup of imagePROGRAF, ColorWave and PlotWave multifunction technical document solutions.

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

Retrieved on: 
Thursday, March 28, 2024

Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.

Key Points: 
  • Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.
  • Since the OTC launch, NARCAN® Nasal Spray can be purchased at more than 32,000 mass drug, grocery, online retailers and e-commerce sites.
  • Emergent is working with retail partners to make it easy to find and access, however each retailer ultimately determines in-store product placement.
  • “That’s why we remain committed to increasing awareness of NARCAN® Nasal Spray availability.